Ann: PTX100 Ph1b results to be presented at specialist congress, page-16

PTX-100, also described as a pan-RhoA inhibitor, has broad potential beyond TCL and even cancer... including cardiovascular disease!

Not sure that PTX-100's claim to fame would be as a cure for CTCL but it certainly appears to offer sufferers cancer-free lives for whatever extended duration that may be. I've been reading up about biomarkers, CDs, monoclonal antibodies, etc. I suspect that everything is being thrown at this opportunity to get PTX-100 not only into a registration trial but into the spotlight as a potential companion drug (perhaps beyond TCL).

Here's an interesting subject title among the presentations at the ASH meeting:

Lymphoma Accelerates Aging Phenotypes and Epigenetic States in Adaptive Immune Cells

I hadn't considered CellPryme as being a candidate for our own TCL Ph2 trial until NOW. Hmmm.... of course, trial investigators need to differentiate the benefit derived from each drug and intervention. Perhaps that is why biomarkers are so important. They can shed light on the mode of action going on within cells at a molecular level. We'd also have the clinical evidence to support both PTX-100 and CellPryme claims as separate technologies and viability as companion therapies.